299 related articles for article (PubMed ID: 31441380)
21. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
22. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.
Ozen E; Gozukizil A; Erdal E; Uren A; Bottaro DP; Atabey N
PLoS One; 2012; 7(8):e42717. PubMed ID: 22912725
[TBL] [Abstract][Full Text] [Related]
23. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
[TBL] [Abstract][Full Text] [Related]
25. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.
Wu JR; Hu CT; You RI; Ma PL; Pan SM; Lee MC; Wu WS
PLoS One; 2015; 10(1):e0114495. PubMed ID: 25607934
[TBL] [Abstract][Full Text] [Related]
26. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
[TBL] [Abstract][Full Text] [Related]
27. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
[TBL] [Abstract][Full Text] [Related]
28. Association between the HGF/c‑MET signaling pathway and tumorigenesis, progression and prognosis of hepatocellular carcinoma (Review).
Meng W; Chen T
Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34278495
[TBL] [Abstract][Full Text] [Related]
29. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
30. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
[TBL] [Abstract][Full Text] [Related]
31. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy.
Heideman DA; Overmeer RM; van Beusechem VW; Lamers WH; Hakvoort TB; Snijders PJ; Craanen ME; Offerhaus GJ; Meijer CJ; Gerritsen WR
Cancer Gene Ther; 2005 Dec; 12(12):954-62. PubMed ID: 15905856
[TBL] [Abstract][Full Text] [Related]
33. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
[TBL] [Abstract][Full Text] [Related]
34. Ginkgolic acid suppresses the invasion of HepG2 cells via downregulation of HGF/c‑Met signaling.
Li H; Meng X; Zhang D; Xu X; Li S; Li Y
Oncol Rep; 2019 Jan; 41(1):369-376. PubMed ID: 30320342
[TBL] [Abstract][Full Text] [Related]
35. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Lee KH; Choi EY; Hyun MS; Jang BI; Kim TN; Lee HJ; Eun JY; Kim HG; Yoon SS; Lee DS; Kim JH; Kim JR
Clin Exp Metastasis; 2008; 25(1):89-96. PubMed ID: 17992475
[TBL] [Abstract][Full Text] [Related]
36. Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1/2-AP1 and SP1 Axis.
Rhee H; Kim HY; Choi JH; Woo HG; Yoo JE; Nahm JH; Choi JS; Park YN
Cancer Res; 2018 Apr; 78(7):1619-1631. PubMed ID: 29363547
[TBL] [Abstract][Full Text] [Related]
37. SENP1 regulates hepatocyte growth factor-induced migration and epithelial-mesenchymal transition of hepatocellular carcinoma.
Zhang W; Sun H; Shi X; Wang H; Cui C; Xiao F; Wu C; Guo X; Wang L
Tumour Biol; 2016 Jun; 37(6):7741-8. PubMed ID: 26695141
[TBL] [Abstract][Full Text] [Related]
38. STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway.
Zhang R; Gao X; Zuo J; Hu B; Yang J; Zhao J; Chen J
Cancer Sci; 2020 Feb; 111(2):406-417. PubMed ID: 31785057
[TBL] [Abstract][Full Text] [Related]
39. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway.
Yao Y; Dou C; Lu Z; Zheng X; Liu Q
Cell Physiol Biochem; 2015; 35(3):983-96. PubMed ID: 25660117
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor and hepatocyte growth factor cooperate to enhance cell proliferation, scatter, and invasion in murine mammary epithelial cells.
Accornero P; Miretti S; Starvaggi Cucuzza L; Martignani E; Baratta M
J Mol Endocrinol; 2010 Feb; 44(2):115-25. PubMed ID: 19850646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
